On October 5, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, reported that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the oral presentation are as follows:
Abstract Number: 517
Presentation Type: Oral Presentation
Presentation Date: Saturday, November 7, 2026
Presentation Time: 4:30-4:45 p.m. MST
Session: Oral Session 3, 3:30-4:50 p.m. MST
Location: Phoenix Convention Center, Room 301D, Phoenix, Arizona
Title: "MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease."
(Press release, Medicenna Therapeutics, OCT 5, 2026, View Source [SID1234673202])